46
Participants
Start Date
January 18, 2013
Primary Completion Date
June 30, 2016
Study Completion Date
February 28, 2018
Rifaximin
subject will receive three capsules of rifaximin (183.3 mg each) by mouth twice daily (total 1100 mg Daily)
Placebo
subject will receive three capsules of placebo by mouth twice daily.
University of Pittsburgh, Pittsburgh
Walter Reed National Medical Center, Bethesda
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
University of Pittsburgh
OTHER
Walter Reed National Military Medical Center
FED
National Cancer Institute (NCI)
NIH